Patients with Severe Psoriasis Need Evaluation of Heart Disease Risk
Link to psoriasis strengthens evidence that inflammation contributes to coronary artery disease, say editors of The American Journal of Cardiology
New York, 18 December 2008 – According to new recommendations in the December 10 issue of The American Journal of Cardiology (AJC), published by Elsevier, new research is called for and patients with severe forms of the skin disease psoriasis should receive evaluation and possible treatment to reduce their risk of coronary artery disease (CAD).
Psoriasis is a common skin disease affecting two to three percent of the world population, including 7.5 million Americans. The most common type of psoriasis causes a scaly rash that can cover large areas of the skin; some patients develop arthritis as well. In addition, there is now strong evidence that people with psoriasis are at increased risk of CAD - narrowing of the arteries supplying the heart, which can lead to heart attack (myocardial infarction) and other complications.
A special "Editor's Consensus" article provides an update on the little-recognized link between psoriasis and heart disease. “This AJC Editor’s Consensus focuses on a large new area of evidence strengthening the connection between inflammatory processes and coronary artery disease," comments cardiologist and lead author of the article, Vincent E. Friedewald, M.D., of the University of Notre Dame. Dr. Friedewald is also an Assistant Editor of AJC. "It is a particularly interesting and unique document in that it bridges current knowledge from two medical disciplines - dermatology and cardiology - that rarely interrelate."
"This consensus statement, issued by an expert panel of cardiologists, dermatologists, and scientists, calls for a new standard of care for patients with moderate to severe psoriasis," comments University of Pennsylvania dermatologist Joel M. Gelfand, M.D. "Based on the evolving science, we recommend that patients with moderate to severe psoriasis be educated about the association of psoriasis and cardiovascular disease and that these patients receive appropriate screening and treatment of modifiable cardiovascular risk factors."
The explanation for the link between psoriasis and CAD risk is not yet clear, but a leading candidate is inflammation. Regardless of the cause, the expert panel believes that the current evidence is strong enough to recommend that doctors assess CAD risk in their patients with psoriasis. Key recommendations in the consensus statement include:
• Informing patients with moderate to severe psoriasis that they are at increased risk of CAD and performing a medical evaluation to assess cardiovascular risk. For patients with milder psoriasis, evaluation is recommended if other CAD risk factors are present, such as obesity or high blood pressure.
• Prescribing treatment to reduce high cholesterol levels and other risk factors, if present.
• Paying close attention to possible interactions or adverse effects of the medications used to treat psoriasis.
# # #
About The American Journal of Cardiology
Published 24 times a year, The American Journal of Cardiology® is an independent journal designed for cardiovascular disease specialists and internists with a subspecialty in cardiology throughout the world. AJC is an independent, scientific, peer-reviewed journal of original articles that focus on the practical, clinical approach to the diagnosis and treatment of cardiovascular disease. AJC has one of the fastest acceptance to publication times in Cardiology. Features report on systemic hypertension, methodology, drugs, pacing, arrhythmia, preventive cardiology, congestive heart failure, valvular heart disease, congenital heart disease, and cardiomyopathy. Also included are editorials, readers' comments, and symposia.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
+1 215 239 3671